Fig. 4From: Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDAMean value contributions* of each quantitative criterion and overall MCDA value estimates†for lenvatinib for RR-DTC from the French (a), Italian (b), and Spanish (c) panels versus watchful waiting (1) and sorafenib (2). * Value contribution = Normalized weight ×standardized score; †Overall Value Estimate = ∑ Value contribution of all 12 criteria. Error bars show standard deviations across 8 panelists in each country-specific panelBack to article page